GEN Exclusives

More »

GEN News Highlights

More »
Mar 11, 2008

Nonprofit Organization Receives License for Anti-HIV Candidate from Merck & Co.

  • Merck & Co. will provide a royalty-free license to the International Partnership for Microbicides (IPM) to develop an antiretroviral compound for use as a vaginal microbicide.

    The compound, called L'644, is a member of a class of antiretroviral molecules known as gp41 fusion inhibitors, which inhibit HIV infection by preventing the virus from fusing with the surface of target cells.

    Under the terms of the agreement, Merck grants IPM the rights to develop L'644 in developing countries. The firm will collaborate with IPM to advance early-stage development research efforts.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?